GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
Recruiting · NCT04731272 · Registry updated 2026-05-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Infant, Newborn, Diseases, Nutritional and Metabolic Diseases, cystic fibrosis, diabetes mellitus, endocrine system disorder, exocrine pancreatic insufficiency, glucose intolerance, glucose metabolism disease, hereditary disease, hyperglycemia, lung disorder, metabolic disease, pancreas disorder, respiratory system disorder | Recruiting | Phase 2 | 2026-05-18 | NCT04731272 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Children's Hospital Colorado | 46 |
| Children's Hospital of Philadelphia | 215 |
| University of Pennsylvania | 502 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Children's Hospital of Colorado | Aurora | United States | 28 |
| University of Pennsylvania | Philadelphia | United States | 507 |